Bristol Myers Merck-partnered blood most cancers remedy succeeds in Section 3 trial (NYSE:BMY)

Bristol Myers Squibb (NYSE:BMY) introduced Monday that Reblozyl, an FDA-approved anemia remedy the corporate develops in partnership with Merck (NYSE:MRK), reached the first and key secondary endpoints in a Section 3 trial involving sufferers with myelodysplastic syndromes.

The open-label, randomized examine named COMMANDS was designed to guage Reblozyl versus epoetin alfa, a organic treatment just like human erythropoietin, in sufferers with low/low/intermediate-risk (MDS).

The trial topics had been crimson blood cell (RBC) transfusion-dependent and had not beforehand acquired erythropoiesis-stimulating brokers.

An interim evaluation of the examine has indicated that Reblozyl met the first endpoint exhibiting a “extremely statistically important and clinically significant enchancment” in RBC transfusion independence with a parallel enhance in hemoglobin as a first-line remedy for adults with MDS.

Bristol Myers (BMY) stated that Reblozyl, also referred to as luspatercept-aamt, demonstrated a security profile consistent with findings from one other Section 3 trial known as MEDALIST examine.

The corporate plans to conduct a whole evaluation of COMMANDS information for a presentation at an upcoming medical occasion and intends to share the outcomes with well being authorities.

Learn: Wedbush launched its protection on Geron Company (GERN) on Friday with a bullish view evaluating its experimental MDS remedy imetelstat with Reblozyl.